Clinical Trial Update: MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy) [Phase 2]

View source ↗

Summary

Phase 2 trial update for MNK6106 in hepatic cirrhosis with hepatic encephalopathy (HE) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Cirrhosis
• Hepatic Encephalopathy

Drugs mentioned

• MNK6106

Snippet

Sponsor: Mallinckrodt | Conditions: Hepatic Cirrhosis, Hepatic Encephalopathy (HE) | Phase 2 | Status: COMPLETED | Results posted: 2021-07-20